Uncovered in Q2 — book value still falling. The $0.18 quarterly dividend, $0.72 annualized, was held unchanged, but second-quarter earnings available for distribution (EAD) of $0.15 a share did not cover it — a 120% payout, after first-quarter EAD of $0.21 had covered the same dividend. The quarter also produced a GAAP net loss of $0.03 a share, and book value fell from $7.12 at March 31 to $6.90 at June 30, down from $7.36 at December 31, 2025. No return-of-capital funding of the dividend was verified in the filings checked, so this stays a warning rather than a trap verdict — but a 22.6% yield on a share price down sharply over the past year is distress pricing, not a safe rate, and the dividend now depends on EAD recovering above $0.18.
Key risk: Mortgage-banking and spread income falling short of the dividend — second-quarter EAD already missed it, and with roughly 5× recourse leverage, valuation swings move book value faster than operating income can rebuild it.
Changes if: EAD falls below the $0.18 quarterly dividend for a second straight quarter, book value falls for a third straight quarter, or recourse leverage rises materially past the second-quarter level. Any of those turns an uncovered quarter into a cut question, and a sustained EAD shortfall would force a re-grade.
- ✗EAD coverage check: Second-quarter EAD of $0.15 a share covered only 83% of the $0.18 dividend, down from $0.21 in the first quarter — the dividend was paid out of more than the quarter earned on this measure.
- !Book-value check: Book value fell from $7.36 at December 31, 2025 to $7.12 at March 31 and $6.90 at June 30, 2026 — down about 6% in six months while the dividend was held flat.
- !Leverage check: About 5× recourse leverage at June 30, on roughly $4.5 billion of recourse debt, is what turns valuation moves into book-value losses — the structure amplifies every spread move, in both directions.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.